Advertisement

Topics

Mylan Slides on North American Sales Drop, Uncertainty over Generic Approvals

00:09 EDT 10 Aug 2017 | Topix

Mylan NV on Wednesday, Aug. 9, reported second-quarter numbers that came in below analysts' estimates amid pricing pressures facing the sector. The company "had a challenging quarter in North America with pressures arising from both accelerated new approvals on our existing generic products and continued consolidation of our U.S. customer base," said chief commercial officer Anthony Mauro on the earnings call.

Original Article: Mylan Slides on North American Sales Drop, Uncertainty over Generic Approvals

NEXT ARTICLE

More From BioPortfolio on "Mylan Slides on North American Sales Drop, Uncertainty over Generic Approvals"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...